Literature DB >> 31840801

Successful treatment of a PNH patient non-responsive to eculizumab with the novel complement C5 inhibitor coversin (nomacopan).

Saskia Schols1, Miles A Nunn2, Ian Mackie3, Wynne Weston-Davies2, Jun-Ichi Nishimura4, Yuzuru Kanakura4, Nicole Blijlevens1, Petra Muus1,5, Saskia Langemeijer1.   

Abstract

Entities:  

Keywords:  complement; coversin; haemolysis; nomacopan; paroxysmal nocturnal haemoglobinuria

Year:  2019        PMID： 31840801     DOI： 10.1111/bjh.16305

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  8 in total

Review 1.  Targeting the complement system in neuromyelitis optica spectrum disorder.

Authors:  Nithi Asavapanumas; Lukmanee Tradtrantip; Alan S Verkman
Journal:  Expert Opin Biol Ther       Date:  2021-02-16       Impact factor: 5.589

Review 2.  Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway.

Authors:  Marion Ort; Jasper Dingemanse; John van den Anker; Priska Kaufmann
Journal:  Front Immunol       Date:  2020-12-10       Impact factor: 7.561

Review 3.  Immunological Basis of the Endometriosis: The Complement System as a Potential Therapeutic Target.

Authors:  Chiara Agostinis; Andrea Balduit; Alessandro Mangogna; Gabriella Zito; Federico Romano; Giuseppe Ricci; Uday Kishore; Roberta Bulla
Journal:  Front Immunol       Date:  2021-01-11       Impact factor: 7.561

4.  Clinical observation of low-dose combination chemotherapy in refractory/recurrent paroxysmal nocturnal hemoglobinuria patients: A single-center retrospective analysis.

Authors:  Liyan Li; Hui Liu; Honglei Wang; Zhaoyun Liu; Yingying Chen; Chunyan Liu; Xiaoyu Zhao; Lijuan Li; Huaquan Wang; Zonghong Shao; Rong Fu
Journal:  J Clin Lab Anal       Date:  2022-01-14       Impact factor: 2.352

Review 5.  Role of Complement System in Kidney Transplantation: Stepping From Animal Models to Clinical Application.

Authors:  Ruochen Qi; Weijun Qin
Journal:  Front Immunol       Date:  2022-02-25       Impact factor: 7.561

6.  Dual inhibition of complement component 5 and leukotriene B4 by topical rVA576 in atopic keratoconjunctivis: TRACKER phase 1 clinical trial results.

Authors:  Sara Sánchez-Tabernero; Julia Fajardo-Sanchez; Wynne Weston-Davies; Mohit Parekh; Jaime Kriman; Stephen Kaye; Sajjad Ahmad
Journal:  Orphanet J Rare Dis       Date:  2021-06-11       Impact factor: 4.123

Review 7.  Halting targeted and collateral damage to red blood cells by the complement system.

Authors:  M Jalink; E C W de Boer; D Evers; M Q Havinga; J M I Vos; S Zeerleder; M de Haas; I Jongerius
Journal:  Semin Immunopathol       Date:  2021-06-30       Impact factor: 9.623

Review 8.  Tipping the balance: intricate roles of the complement system in disease and therapy.

Authors:  Richard B Pouw; Daniel Ricklin
Journal:  Semin Immunopathol       Date:  2021-10-26       Impact factor: 9.623
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.